Prognostic Assessment and Risk Stratification: Early Insight into Metastatic Risk

Precisely quantifies CTC abundance in peripheral blood and sensitively captures highly metastatic "CTC clusters". Independently predicts patients’ overall survival (OS) and progression-free survival (PFS), enabling clinicians to accurately identify high-risk subgroups at the initial diagnosis stage.

Dynamic Therapeutic Monitoring: A "Real-Time Radar" Ahead of Imaging

Eliminates the months-long lag of traditional imaging assessments. By real-time tracking dynamic changes in CTC counts and the expression of proteins such as PD-L1, it promptly and accurately evaluates the true response to chemotherapy, targeted therapy, and immunotherapy, avoiding pseudo-progression and ineffective treatment.

Companion Diagnostics and Medication Guidance: Deciphering Heterogeneity to Identify Precision Targets

Conducts in-depth molecular phenotypic analysis at the single-CTC level. Precisely captures key resistance and targetable mutations such as AR-V7, HER2, and KRAS, effectively overcoming tumor spatial heterogeneity. This provides a solid basis for timely adjustment of targeted and combination therapy regimens for advanced patients.

MRD Detection and Recurrence Early Warning: Proactive Intervention to Prevent Recurrence

Applied to the follow-up of minimal residual disease (MRD) after curative resection. Issues biochemical or histological recurrence warnings months in advance compared to conventional imaging and serum markers. It perfectly complements ctDNA testing, advancing into the Liquid Biopsy 2.0 era for comprehensive assessment of tumor burden and invasive status.

Viable Cell Capture and Drug Sensitivity Screening: Lighting the Way for Advanced Patients

Leveraging non-damaging enrichment technology, it successfully captures high-purity "viable CTCs". It supports the in vitro construction of CTC-derived organoids (CTCDOs) to directly perform high-throughput, individualized drug screening, helping patients who have failed multiple lines of therapy precisely identify effective new drugs.